Hepatology Unit, University of Tor Vergata, Rome 00133, Italy.
Postgraduate School in Hepato/Gastroenterology, Catholic University Our Lady of Good Counsel, Tirana 1004, Albania.
World J Gastroenterol. 2023 Oct 7;29(37):5305-5312. doi: 10.3748/wjg.v29.i37.5305.
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that is observed more frequently in middle-aged women. This disorder is considered an autoimmune disease, since liver injury is sustained by the presence of self-directed antimitochondrial antibodies targeting the bile duct cells. The prognosis may vary depending on an early diagnosis and response to therapy. However, nearly a third of patients can progress to liver cirrhosis, thus requiring a liver transplant. Traditional immunosuppressive therapies, commonly employed for other autoimmune diseases, have limited effects on PBC. In fact, dramatic functional changes that occur in the biliary epithelium in the course of inflammation play a major role in perpetuating the injury. In this minireview, after a background on the disease and possible predisposing factors, the sequential cooperation of cellular/molecular events leading to end-stage PBC is discussed in detail. The rise and maintenance of the autoimmune process, as well as the response of the biliary epithelia during inflammatory injury, are key factors in the progression of the disease. The so-called "ductular reaction (DR)", intended as a reactive expansion of cells with biliary phenotype, is a process frequently observed in PBC and partially understood. However, recent findings suggest a strict relationship between this pathological picture and the progression to liver fibrosis, cell senescence, and loss of biliary ducts. All these issues (onset of chronic inflammation, changes in secretive and proliferative biliary functions, DR, and its relationship with other pathological events) are discussed in this manuscript in an attempt to provide a snapshot, for clinicians and researchers, of the most relevant and sequential contributors to the progression of this human cholestatic disease. We believe that interpreting this disorder as a multistep process may help identify possible therapeutic targets to prevent evolution to severe disease.
原发性胆汁性胆管炎(PBC)是一种慢性胆汁淤积性肝病,多见于中年女性。这种疾病被认为是一种自身免疫性疾病,因为肝损伤是由针对胆管细胞的自身定向抗线粒体抗体持续存在引起的。预后可能因早期诊断和对治疗的反应而异。然而,近三分之一的患者可能会发展为肝硬化,因此需要进行肝移植。传统的免疫抑制疗法,常用于治疗其他自身免疫性疾病,对 PBC 的疗效有限。事实上,炎症过程中胆管上皮发生的剧烈功能变化在持续损伤中起着重要作用。在这篇综述中,在介绍了疾病和可能的诱发因素之后,详细讨论了导致终末期 PBC 的细胞/分子事件的顺序协同作用。自身免疫过程的兴起和维持,以及炎症损伤过程中胆管上皮的反应,是疾病进展的关键因素。所谓的“胆管反应(DR)”,是指具有胆管表型的细胞的反应性扩张,在 PBC 中经常观察到,并且在一定程度上被理解。然而,最近的发现表明,这种病理图像与向肝纤维化、细胞衰老和胆管丧失的进展之间存在严格的关系。本文讨论了所有这些问题(慢性炎症的发生、分泌和增殖性胆管功能的变化、DR 及其与其他病理事件的关系),试图为临床医生和研究人员提供一个有关这种人类胆汁淤积性疾病进展的最相关和顺序贡献者的快照。我们相信,将这种疾病解释为一个多步骤的过程可能有助于确定预防严重疾病进展的可能治疗靶点。